Stocks · News reference
Reported Earlier, Zentalis Pharmaceuticals Prices Underwritten Public Offering Of 23M Shares At $3.50 Per Share, Expects $80.5M Gross Proceeds
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Leerink Partners Assumes Zentalis Pharmaceuticals at Outperform, Raises Price Target to $8
This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales
William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.
William Blair Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating
William Blair analyst Matt Phipps initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating.